Brief: Praxis Precision Medicines Announces Alignment With FDA
09/12/2025 21:05
Dec 9 (Reuters) - Praxis Precision Medicines Inc PRAX.O: PRAXIS PRECISION MEDICINES ANNOUNCES ALIGNMENT WITH FDA ON SIMPLIFIED AND ACCELERATED REGISTRATIONAL PATHWAY FOR ELSUNERSEN IN EARLY ONSET SCN2A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY PRAXIS PRECISION MEDICINES INC: FDA AGREED TO PROPOSED CHANGES TO EMBRAVE3 TRIAL DESIGN TO BE A SINGLE-ARM, BASELINE-CONTROLLED STUDY PRAXIS PRECISION MEDICINES INC: TOPLINE RESULTS FROM ONGOING EMBRAVE STUDY (PART A, N=9) EXPECTED IN 1H 2026 Source text: ID:nGNXlrcr5 Further company coverage: PRAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Praxis Precision Medicines
See all newsUS RESEARCH ROUNDUP-Arxis, Cigna, Vylor
Brief: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings Summary
Praxis Precision Q2 net loss widens on higher expenses
Brief: Praxis Precision Q2 EPS USD -2.87